Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Subscribe To Our Newsletter & Stay Updated
